Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016;20(3):220-4.
doi: 10.5114/wo.2016.61563. Epub 2016 Aug 4.

Can we find a good biochemical marker of early cardiotoxicity in children treated with haematopoietic stem cell transplantation?

Agnieszka Zaucha-Prażmo  1 , Elżbieta Sadurska  2 , Katarzyna Drabko  1 , Jerzy R Kowalczyk  1
Affiliations

Can we find a good biochemical marker of early cardiotoxicity in children treated with haematopoietic stem cell transplantation?

Agnieszka Zaucha-Prażmo et al. Contemp Oncol (Pozn). 2016.

Abstract

Cardiotoxicity is one of the complications following haematopoietic stem cell transplantation (HSCT), but its diagnosis may be hampered due to the presence of different post-transplant comorbidities. The aim of the study was to assess the incidence of cardiac complications and the significance of biochemical markers (NT-proBNP, ANP, ET-1, and TnI) and ECHO systolic and diastolic parameters analysis in children treated with HSCT. Thirty consecutive children (median age 9.6 years) were included in the study. The control group consisted of 14 healthy children (median age of 10.9 years). None of the transplanted children developed clinical cardiotoxicity. Median ET-1 and NT-proBNP plasma levels were elevated when compared to controls in at least 3 out of 4 analysed time points, median ANP levels differed only in one time point, and no difference was found between median TnI values in all analysed time points. Echocardiographic systolic parameters were within the normal range, while median E/A ratio assessed before HSCT, on day +30, and +100 post-transplant was statistically lower in HSCT patients (respectively, 1.34, 1.37, and 1.42 vs. 1.73). It confirms the need for careful follow up in patients who have received chemotherapy and have been treated with HSCT.

Keywords: biochemical markers; cardiotoxicity; haematopoietic stem cell transplantation.

PubMed Disclaimer

References

    1. Eames GM, Crosson J, Steinberger J, et al. Cardiovascular function in children following bone marrow transplant: a cross-sectional study. Bone Marrow Transplant. 1997;19:61–6. - PubMed
    1. Snowden JA, Hill G, Hunt P, et al. Assessment of cardiotoxicity during haematopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant. 2000;26:309–13. - PubMed
    1. Murdych T, Weisdorf DJ. Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977-1997. Bone Marrow Transplant. 2001;28:283–7. - PubMed
    1. Jiji RS, Kramer CM, Salermo M. Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs. J Nucl Cardiol. 2012;19:377–88. - PMC - PubMed
    1. Tichelli A, Bhatia S, Socie G. Cardiac and cardiovascular cosequences after haematopoietic stem cel transplantation. Br J Heaematol. 2008;142:11–26. - PubMed